• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update

    3/29/23 4:05:12 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCEL alert in real time by email

    ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression

    Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year

    APN-497444 and APN-346958 programs advancing with nomination of clinical candidates expected in 2023

    Conference call and webcast with accompanying slides scheduled for today at 4:30 p.m. EDT

    SAN CARLOS, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the fourth quarter and full-year ended December 31, 2022, and provided an overview of recent developments.

    "Last year was a productive time for Atreca, with advances made in our discovery platform, preclinical programs, and ATRC-101," said John Orwin, Chief Executive Officer of Atreca. "Today we are pleased to report additional data from our ongoing Phase 1b trial, which show that ATRC-101 continues to be well tolerated, and that longer progression free survival was observed in patients with high target expression in this early trial. Patient enrollment based on target expression is ongoing in both the monotherapy and combination cohorts of the study and we expect to report additional data and go/no-go decisions for Phase 2 development toward the end of this year."

    "We believe these data further validate the ability of our proprietary platform to identify potentially valuable therapeutic antibodies against novel targets in oncology," Mr. Orwin added. "Continued investments in our discovery platform have accelerated the growth of our preclinical pipeline, and we look forward to nominating our next two clinical candidates later this year."

    ATRC-101 Update

    • The Phase 1b trial is a first-in-human, open-label study of ATRC-101 as monotherapy and in combination with pembrolizumab in patients with select solid tumor cancers. Once every 3-week (Q3W) and once every 2-week (Q2W) schedules have been evaluated at dose levels up to 30 mg/kg with no dose-limiting toxicities observed. Enrollment is ongoing at the 30 mg/kg ATRC-101 dose level in both the Q3W monotherapy and combination arms of the trial, with participants selected based on target expression.

    As of the data cut-off date of February 17, 2023, a total of 71 participants had been dosed in the trial and evaluated for safety, with 62 participants receiving either the 3, 10 or 30 mg/kg dose including 42 participants treated in the Q3W monotherapy arm, 11 in the Q2W monotherapy arm, and 9 in the combination arm. Participants enrolled in the study had received a median of five prior lines of treatment. All participants in the combination arm had experienced an unsatisfactory tumor response or progression following prior anti-PD-1 or anti-PD-L1 therapy.

    • ATRC-101 has been generally well-tolerated. For the 71 participants enrolled, most of the reported adverse events were grade ≤ 2. Only two grade 3 AEs were considered potentially treatment-related, which were one instance each of headache and a small intestinal obstruction. The most common treatment-related AEs were fatigue (n=17, 24%) and pain (n=14, 20%), with no serious adverse events determined to be related to treatment with ATRC-101.

    • The Company continued to observe that high target expression (as defined by an H-score ≥50) discriminates for anti-tumor activity in the 3, 10 and 30 mg/kg dose cohorts. Among the 17 participants with a high target expression at screening treated with monotherapy at the higher dose levels, disease control was observed in 59% (10 of 17 patients) including 9 (53%) patients with stable disease (SD) and one (6%) patient with a partial response (PR). With combination patients included, disease control was observed in 58% (n=14 of 24) including 12 (50%) SD , 1 (4%) PR and 1 (4%) CR. By comparison, in participants with a screening H-score < 50 (low), disease control was 25% (6 of 24 patients) with SD as the best overall response for all patients in the monotherapy cohort. A similar result was observed when including combination patients with 6 of 25 (24%) achieving SD as a best overall response, with none achieving PR or better.

    • Longer progression free survival was observed in patients with high target expression treated in the 3, 10 and 30 mg/kg dose cohorts. A hazard ratio of 0.47 was observed in a Kaplan Meier analysis of monotherapy patients treated at the higher dose levels separated by H-score (n=41), and a hazard ratio of 0.40 was observed in the Kaplan Meier analysis of combination therapy patients separated by H-score (n=49). The previously reported PR observed in a lung cancer patient and CR observed in a melanoma patient were durable, with a PR extending beyond 300 days and a CR ongoing (418 days as of data cut-off date).

    • Atreca is continuing to enroll subjects in both the Q3W monotherapy and combination therapy cohorts at the 30 mg/kg dose level, with a focus on the recruitment of H-score high participants across tumor types. Additional data from the ongoing study will inform a future decision concerning whether to advance ATRC-101 into Phase 2 studies and in which indications. Atreca expects to report additional data from the Phase 1b study and provide details on its potential Phase 2 development plans by the end of 2023.  

    "These results are encouraging and reinforce our belief in the therapeutic potential of ATRC-101. Importantly, they support the relationship we've observed between target expression and both ATRC-101's anti-tumor activity and duration of response," added Dr. Philippe Bishop, Chief Medical Officer of Atreca. "We look forward to providing a development update with go/no-go decisions later this year."

    Preclinical Pipeline and Discovery Platform

    • APN-497444 (‘444) is an Atreca-discovered antibody targeting a novel, tumor-specific glycan. ‘444 displays uniform and tumor-selective binding with high target prevalence in colorectal cancer and exhibits compelling pre-clinical anti-tumor activity and initial safety when weaponized as an ADC. Atreca expects to nominate a clinical candidate from the program in 2023 and is targeting an IND submission in late 2024.

    • APN-346958 (‘958) is a tumor-selective antibody discovered by Atreca recognizing an RNA-binding protein target. ‘958 exhibits compelling pre-clinical anti-tumor activity and initial safety accompanied by robust immune activation and T cell expansion when weaponized as a T cell bispecific antibody. ‘958 was mutually selected as the first joint program combining an Atreca-discovered antibody with Xencor's XmAb® bispecific Fc domain and a cytotoxic T-cell binding domain (CD3), with Atreca leading preclinical and clinical development. Atreca and Xencor expect to name a candidate from the program in 2023 and target an IND submission by early 2025.

    • MAM01/ATRC-501 is a novel, Atreca-discovered antibody licensed to the Gates Medical Research Institute ("Gates MRI") for the prevention of malaria. Gates MRI is preparing to file an IND for MAM01/ATRC-501 in 2023. Atreca retains commercial rights in the U.S., Europe and parts of Asia, and potential product development opportunities in those regions include prophylaxis for those traveling to malaria endemic regions.

    • Pipeline expansion has been accelerated by continued investments in the discovery platform, which have enabled Atreca to generate leads against novel targets more efficiently.

    Other Recent Developments and Highlights

    • In February 2023, Atreca and Xencor, Inc. announced the mutual selection of the first program combining an Atreca-discovered antibody with Xencor's XmAb® bispecific Fc domain and a cytotoxic T-cell binding domain (CD3) under their 2020 strategic collaboration agreement.

    • In January 2023, Atreca announced the appointment of Philippe Bishop, MD, as Chief Medical Officer.

    Fourth Quarter and Full-year 2022 Financial Results

    • As of December 31, 2022, cash and cash equivalents and investments totaled $70.5 million.
    • Research and development expenses for the year ended December 31, 2022, were $66.8 million, including non-cash share-based compensation expense of $7.9 million. Research and development expenses for the three months ended December 31, 2022, were $13.8 million, including non-cash share-based compensation expense of $1.3 million.
    • General and administrative expenses for the year ended December 31, 2022, were $31.5 million, including non-cash share-based compensation expense of $9.0 million. General and administrative expenses for the three months ended December 31, 2022, were $7.5 million, including non-cash share-based compensation expense of $1.9 million.
    • Atreca reported a net loss of $97.2 million, or basic and diluted net loss per share attributable to common stockholders of $2.52, for the year ended December 31, 2022. The Company reported a net loss of $21.3 million, or basic and diluted net loss per share attributable to common stockholders of $0.55, for the three months ended December 31, 2022.

    Conference Call and Webcast Details

    Atreca will host a live conference call and webcast, including accompanying slides, today at 4:30 p.m. EDT. To access the conference call by telephone, please use this link to register and receive the dial-in numbers and unique PIN to access the call. To access the webcast, including accompanying slides, please use this link.

    The conference call registration and a live audio webcast and accompanying slide presentation can also be accessed via the Events section of the Company's investor relations website at https://ir.atreca.com/news-and-events/event-calendar. An archived replay of the webcast will be available on the Company's website for 30 days following the live event.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101, our pipeline of lead-stage oncology programs, and MAM01/ATRC-501, a clinical candidate licensed to the Bill & Melinda Gates Medical Research Institute for the prevention of malaria. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those regarding our strategy and future plans, including statements regarding tolerance of ATRC-101 in our ongoing Phase 1b trial, enrollment of patients in our Phase 1b clinical trial of ATRC-101, our belief that our ATRC-101 data further validates the ability of our proprietary platform to identify potentially valuable therapeutic antibodies against novel targets in oncology, the acceleration of growth of our preclinical pipeline based on continued investments in our discovery platform, our plans for potential Phase 2 development of ACTR-101 by the end of 2023, the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof, data read-outs and the timing thereof, including the reporting of updated data from the monotherapy and pembrolizumab combination arms of our Phase 1b clinical trial of ATRC-101, the advancement of APN-497444 and APN-346958 with the nomination of clinical candidates in 2023, the expected timing of INDs, including delays thereof and plans to submit one additional IND per year in oncology beginning in 2024, and the advancement of MAM01/ATRC-501 by Gates MRI, including plans to file an IND in 2023. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "continue," "progress," "accelerate," "will," "expect," "advance," "target," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.



    Atreca, Inc.

    Condensed Consolidated Balance Sheets

    (in thousands, except share and per share data)

      December 31,December 31, 
          2022   2021     
          
    ASSETS     
              
    Current Assets        
    Cash and cash equivalents $30,819  $94,746  
    Investments  39,676   22,287  
    Prepaid expenses and other current assets  7,531   5,337  
    Total current assets  78,026   122,370  
    Property and equipment, net  37,972   43,015  
    Operating lease right-of-use assets  36,056   -  
    Long-term investments  -   31,042  
    Deposits and other  2,976   3,630  
    Total assets $155,030  $200,057  
              
    LIABILITIES AND STOCKHOLDERS' EQUITY         
              
    Current Liabilities         
    Accounts payable $1,741  $3,352  
    Accrued expenses  9,681   11,555  
    Operating lease liabilities, current portion  3,544   -  
    Other current liabilities  1,327   1,992  
    Total current liabilities  16,293   16,899  
    Deferred rent  -   28,229  
    Operating lease liabilities, net of current portion  60,331   -  
    Total liabilities  76,624   45,128  
              
              
    Stockholders' equity         
    Common stock  4   4  
    Additional paid-in capital  535,592   514,794  
    Accumulated other comprehensive income (loss)  (266)  (102) 
    Accumulated deficit  (456,924)  (359,767) 
    Total stockholders' equity  78,406   154,929  
    Total liabilities and stockholders' equity $155,030  $200,057  
          



    Atreca, Inc.

    Condensed Consolidated Statements of Operations

    (in thousands, except share and per share data)

       Three Months Ended Year Ended
       December 31, December 31,
        2022   2021   2022   2021 
              
    Expenses        
     Research and development $13,767  $22,204  $66,829  $78,349 
     General and administrative  7,536   7,306   31,466   31,954 
     Asset Impairment  449   -   449   - 
     Total expenses  21,752   29,510   98,744   110,303 
    Interest and other income (expense)        
     Other income  20   -   770   851 
     Interest income  387   24   817   207 
     Interest expense  -   -   -   (3)
     Loss on disposal of property and equipment  -   (32)  -   (77)
    Loss before Income tax expense  (21,345)  (29,518)  (97,157)  (109,325)
    Income tax expense  -   -   -   (1)
    Net loss $(21,345) $(29,518) $(97,157) $(109,326)
    Net loss per share, basic and diluted $(0.55) $(0.79) $(2.52) $(2.95)
    Weighted-average shares used in computing        
    net loss per share, basic and diluted  39,067,391   37,493,779   38,593,894   37,038,195 
              





    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    [email protected]

    Investors:

    Alex Gray, 650-779-9251

    [email protected]

    Media:

    Julia Fuller, 858-692-2001

    [email protected]

    Source: Atreca, Inc.

     



    Primary Logo

    Get the next $BCEL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BCEL

    DatePrice TargetRatingAnalyst
    3/4/2022$17.00 → $14.00Buy
    Stifel
    More analyst ratings

    $BCEL
    SEC Filings

    See more
    • SEC Form DEFM14A filed by Atreca Inc.

      DEFM14A - Atreca, Inc. (0001532346) (Filer)

      4/22/24 9:21:58 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PREM14A filed by Atreca Inc.

      PREM14A - Atreca, Inc. (0001532346) (Filer)

      4/11/24 4:52:06 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Atreca Inc.

      15-12G - Atreca, Inc. (0001532346) (Filer)

      4/1/24 4:31:35 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Orwin John A bought $0 worth of Series A Junior Preferred Stock (1 units at $0.01) (SEC Form 4)

      4 - Atreca, Inc. (0001532346) (Issuer)

      4/17/24 7:36:28 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel reiterated coverage on Atreca with a new price target

      Stifel reiterated coverage of Atreca with a rating of Buy and set a new price target of $14.00 from $17.00 previously

      3/4/22 7:37:56 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird resumed coverage on Atreca with a new price target

      Robert W. Baird resumed coverage of Atreca with a rating of Outperform and set a new price target of $27.00 from $30.00 previously

      6/4/21 7:01:08 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Atreca with a new price target

      Jefferies initiated coverage of Atreca with a rating of Buy and set a new price target of $30.00

      2/8/21 5:57:56 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Orwin John A bought $0 worth of Series A Junior Preferred Stock (1 units at $0.01) (SEC Form 4)

      4 - Atreca, Inc. (0001532346) (Issuer)

      4/17/24 7:36:28 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Serafini Tito sold $1,455 worth of shares (20,788 units at $0.07), decreasing direct ownership by 32% to 43,636 units (SEC Form 4)

      4 - Atreca, Inc. (0001532346) (Issuer)

      4/3/24 9:50:22 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orwin John A sold $8,597 worth of shares (22,951 units at $0.37), decreasing direct ownership by 23% to 77,541 units (SEC Form 4)

      4 - Atreca, Inc. (0001532346) (Issuer)

      4/3/24 9:37:17 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immunome to Acquire Antibody-Related Assets and Materials from Atreca

      Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Atreca, Inc. (NASDAQ:BCEL) to acquire a collection of antibody-related assets and materials. "We believe that novel and underexplored targets will drive the next generation of transformative ADCs. These antibody-related assets will expand our toolbox, complementing our existing programs as we advance our mission of developing innovative treatments for cancer patients," stated Clay B. Siegall, Ph.D., Chairman and Chief Executive Officer of Immunome. Under the terms of the ass

      12/26/23 8:30:00 AM ET
      $BCEL
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome

      CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. ("Atreca") (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it entered into a definitive asset purchase agreement with Immunome, Inc. (NASDAQ:IMNM) to sell a collection of antibody-related assets and materials. Under the terms of the agreement, Immunome would pay Atreca up to $12.5 million, consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones. "We are pleased to announce this asset purchase agreement with Immunome, a com

      12/26/23 8:30:00 AM ET
      $BCEL
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives

      SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today reported financial results for the third quarter ended September 30, 2023, and announced that the Company is implementing a further reduction in its workforce of approximately 40% while maintaining the necessary support to continue exploring potential strategic transactions and business alternatives. "Since our founding, Atreca has leveraged a unique discovery platform to identify numerous antibodies binding no

      11/14/23 4:30:08 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Leadership Updates

    Live Leadership Updates

    See more
    • Atreca Appoints Philippe Bishop, MD as Chief Medical Officer

      SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Philippe Bishop, MD, as Chief Medical Officer (CMO), effective immediately. "Dr. Bishop is a tremendous addition to the Atreca team at an important time in the clinical development of ATRC-101. As an accomplished executive and medical oncologist with extensive experience in cancer drug development, his leadership and expertise will be invaluable as we continue to advance ATRC-101, a

      1/9/23 8:30:54 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer

      - Industry Veterans Expand Company's Business and Operations Functions Cellino Biotech, Inc., an autonomous cell therapy technology platform company, today announced the expansion of its executive leadership team with the appointments of Abhijit (Abhi) Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Senior Vice President (SVP) and Chief Business Officer. Together, these leaders will support the company's growth and further enhance its ability to build an integrated technology platform for the development and scaling of regenerative medicines. "We are delighted to welcome Abhi and Paulette, who bring invaluable expertise in advanced technology development and business to

      6/27/22 8:00:00 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

      SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Stephen Gould, Ph.D., as Chief Scientific Officer. "Stephen is an exceptional scientific leader with particular experience in the development of weaponized antibody-based therapeutics, and we are excited to welcome him to the Atreca team," said John Orwin, Chief Executive Officer of Atreca. "Our discovery platform has proven to be highly productive in generating promising tumor-sele

      6/16/22 4:05:22 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Atreca Inc.

      SC 13G - Atreca, Inc. (0001532346) (Subject)

      1/10/24 4:52:48 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atreca Inc. (Amendment)

      SC 13G/A - Atreca, Inc. (0001532346) (Subject)

      12/7/22 10:24:32 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atreca Inc. (Amendment)

      SC 13G/A - Atreca, Inc. (0001532346) (Subject)

      2/14/22 4:47:03 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Financials

    Live finance-specific insights

    See more
    • Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update

      ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year APN-497444 and APN-346958 programs advancing with nomination of clinical candidates expected in 2023 Conference call and webcast with accompanying slides scheduled for today at 4:30 p.m. EDT SAN CARLOS, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogati

      3/29/23 4:05:12 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023

      SAN CARLOS, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will host a conference call and webcast on Wednesday, March 29, 2023, at 4:30 p.m. EDT to report financial results and provide an update on its discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101. To access the conference call by telephone, please use this link to register and receive the dial-in numbers and unique PIN to access the call. To acc

      3/23/23 5:00:36 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca Announces Expansion of Preclinical Pipeline

      Atreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate Virtual R&D Day scheduled for today at 4:15 p.m. EDT SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced a licensing agreement with Zymeworks Inc. (Zymeworks) (NYSE:ZYME) to utilize their ZymeLink™ technology to develop novel antibody-drug conjugates (ADCs) and declared ATRC-301, an ADC targeting a novel epitope on EphA2, as the C

      4/5/22 4:01:00 PM ET
      $BCEL
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care